C.K. Coolidge, Inc. (Abridged) Custom Case Solution & Analysis

Evidence Brief: C.K. Coolidge, Inc.

Financial Metrics

Standard Catheter Price: 0.25 per unit (Paragraph 4).
Glow-Line Manufacturing Cost: 0.50 per unit (Exhibit 2).
Proposed Price Points: 0.75, 1.50, and 2.50 (Paragraph 12).
Clinical Infection Rate (Standard): 4 percent (Exhibit 3).
Clinical Infection Rate (Glow-Line): 1 percent (Exhibit 3).
Average Cost per Infection Incident: 28000 (Paragraph 8).
Hospital Reimbursement Model: Fixed payment per diagnosis (DRG), making infection costs an internal hospital expense (Paragraph 9).

Operational Facts

Production Status: FDA approval received; manufacturing facilities prepared for immediate scale (Paragraph 2).
Distribution: Primary sales through Group Purchasing Organizations (GPOs) and direct hospital contracts (Paragraph 5).
Sales Force: Specialized medical device team with existing relationships in intensive care units (Paragraph 6).
Geographic Focus: Initial rollout targeted at United States domestic hospitals (Paragraph 1).

Stakeholder Positions

Tom Philpott (Sales Manager): Advocates for lower pricing (0.75) to secure rapid market share and meet volume targets (Paragraph 14).
CFO: Demands higher margins to recoup Research and Development investment and justify the premium nature of the product (Paragraph 15).
Hospital Administrators: Focused on reducing total cost of care but constrained by departmental budget silos (Paragraph 10).
Infection Control Nurses: Primary influencers who prioritize patient safety and reduction of complications (Paragraph 11).

Information Gaps

Competitor Response: No data on the timeline for rival firms to launch similar antimicrobial coatings.
Long-term Efficacy: Clinical data covers initial trials but lacks five-year longitudinal performance metrics.
GPO Elasticity: Precise price sensitivity of major purchasing groups remains an estimate.

Strategic Analysis

Core Strategic Question

Coolidge must determine if the Glow-Line catheter is a commodity improvement or a clinical solution. The central dilemma is whether to price for volume or price for the economic value created by reducing infections.

Structural Analysis

The medical device market exhibits high supplier power for patented innovations but intense price competition for consumables. The Glow-Line technology shifts the catheter from a high-volume consumable to a strategic tool for cost containment. Under the current fixed-reimbursement environment, hospitals absorb the 28000 cost of every infection. A reduction from 4 percent to 1 percent infection rates translates to an expected saving of 840 per 100 catheters used. Traditional pricing models fail to capture this 8.40 per unit value creation.

Strategic Options

Option 1: Market Penetration (0.75)

Rationale: Minimizes friction for hospital procurement and prevents competitor entry.
Trade-offs: Leaves significant capital on the table; risks branding the product as a low-end commodity.
Resource Requirements: High manufacturing volume and aggressive sales incentives.

Option 2: Value-Based Premium (2.50)

Rationale: Captures a fraction of the 8.40 in clinical savings while signaling superior quality.
Trade-offs: Slower adoption cycle; requires sophisticated selling to hospital executives rather than just procurement.
Resource Requirements: Training for the sales force on economic modeling and total cost of care.

Preliminary Recommendation

Coolidge should set the price at 2.50. The economic argument is irrefutable: hospitals save thousands of dollars for every few cents of additional product cost. Pricing at 0.75 ignores the clinical evidence and wastes the primary competitive advantage. The company must position Glow-Line as a financial instrument for hospital risk management.

Implementation Roadmap

Critical Path

Phase 1 (Days 1-30): Develop Value-in-Use calculators for the sales force to demonstrate hard dollar savings to hospital CFOs.
Phase 2 (Days 31-60): Target top-tier teaching hospitals as early adopters to create clinical pull-through and peer-reviewed validation.
Phase 3 (Days 61-90): Renegotiate GPO contracts using trial data to justify the premium tier placement.

Key Constraints

Budget Silos: Procurement departments often look at unit price while the savings accrue to the general operating fund. Success depends on reaching the decision makers who own the infection risk.
Sales Competency: The current team is used to selling on features; they must transition to selling on financial outcomes.

Risk-Adjusted Implementation Strategy

The rollout will utilize a phased approach. If adoption lags at 2.50 due to budget constraints, the company will offer a shared-savings model or performance-based rebates rather than a flat price cut. This preserves the price integrity of the brand while addressing the liquidity concerns of smaller hospitals.

Executive Review and BLUF

Bottom Line Up Front

Set the Glow-Line price at 2.50 per unit. Any lower price point fails to capture the significant economic value generated by the 75 percent reduction in infection rates. At 2.50, the product remains a massive bargain for hospitals, which save approximately 8.40 in avoided costs for every unit consumed. The focus must shift from selling a device to selling an insurance policy against infection-related losses. This strategy maximizes margin and funds the next generation of development. Approve the 2.50 price immediately to begin GPO negotiations.

Dangerous Assumption

The analysis assumes hospital administrators act rationally across departmental boundaries. In reality, the procurement officer may be incentivized solely on purchase price variance, ignoring the millions saved in the intensive care unit. If Coolidge cannot bridge this internal hospital gap, the premium pricing strategy will stall despite the clear math.

Unaddressed Risks

Regulatory Shift: If Medicare changes reimbursement rules for infections, the economic value could fluctuate rapidly, altering the hospital incentive structure.
Competitor Leapfrogging: A rival may launch a 1.00 catheter that claims similar efficacy without the clinical pedigree, creating a mid-tier that erodes the Coolidge position.

Unconsidered Alternative

The team did not evaluate a razor-and-blade model where the catheters are sold at cost (0.50) in exchange for a multi-year exclusive contract for all hospital consumables. This would lock out competitors entirely and secure the market for a decade, though it would sacrifice immediate margin.